You are here: Industry Insights > Valneva

News List

Positive Phase III results for Valneva’s chikungunya vaccine pharmatimes
August 06, 2021
Valneva’s single-shot chikungunya vaccine candidate, VLA1553, has seen positive topline results from its Phase III pivotal trial. VLA1553 was recently awarded breakthrough designation status by the Food and Drug Administration (FDA).
Valneva’s chikungunya virus vaccine granted breakthrough designation pharmatimes
July 12, 2021
French speciality vaccine company Valneva has announced that its single-shot chikungunya vaccine candidate has received a breakthrough therapy designation from the US Food and Drug Administration (FDA).
Valneva Appoints Ops SVP contractpharma
July 08, 2021
Vincent Dequenne has an extensive track record in the pharmaceutical industry with more than 20 years of manufacturing and production experience.
Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases firstwordpharma
July 06, 2021
ValnevaSE announced today it will host a virtual symposium titled, "Developing new vaccines to protect against infectious diseases at home and abroad" on July 9, at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID）
Valneva completes Phase 3 trial recruitment for its inactivated COVID-19 vaccine candidate worldpharmanews
June 10, 2021
Valneva SE announced that it has completed recruitment for the pivotal Phase 3 trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Valneva’s Inactivated, Adjuvanted COVID-19 Vax Achieves Positive Data contractpharma
April 23, 2021
VLA2001 was highly immunogenic with more than 90% of study participants developing significant levels of antibodies to SARS-CoV-2 virus spike protein.
Valneva Focuses on Bilateral Discussions to Supply COVID-19 Vax contractpharma
April 23, 2021
Valneva SE is now focusing on discussions, on a country by country basis, to supply its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, and is consequently deprioritizing the ongoing centralized discussions with the European Commission (EC).
Valneva Switches Focus to Bilateral Discussions to Supply its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001 americanpharmaceuticalreview
April 22, 2021
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced it is now focusing on bilateral discussions ...
Scottish COVID-19 vaccine shows ‘strong immune response’ in early UK trials expresspharma
April 08, 2021
The vaccine, called VLA2001, also induced T-cell responses, which help the body fend off a virus and determine long-lasting immunity.
Valneva reports positive Phase 1/2 data for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001 worldpharmanews
April 07, 2021
Valneva SE announced positive data for Part A of the Phase 1/2 clinical trial of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Previous page 1 2 3 4 5 Next page